Topic Listing for LILLY ELI & CO

Allocation Purchase Price Amendments Articles Incorporation Bylaws Change
Animal Health Products Annual Meeting Admission Ticket
Appendix Application Critical Accounting Policies
Applied Molecular Evolution Inc Acquisition Asset Impairments Related Restructuring Other Charges
Asset Impairments Related Restructuring Other Special Charges Notes Asset Impairments Restructuring Other Special Charges
Available Information Web Site Background
Boehringer Ingelheim Borrowings
Bristol-myers Squibb Business Development
Business Development Recent Product Late-stage Pipeline Developments Changes Internal Controls
Code Ethics Collaborations
Competition Consolidated Statements Comprehensive Income
Consolidated Statements Comprehensive Income Loss Consolidated Statements Operations
Contingencies Corporate Governance
Costs Associated Exit Disposal Activities Creation Direct Financial Obligation Off-balance Sheet Arrangement
Cymbalta Departure Directors Certain Officers Election Appointment Compensatory
Departure Directors Principal Officers Election Appointment Director Independence
Directors Executive Officers Disclosure Controls Procedures
Earnings Loss Per Share Effect Risk-management Instruments Statement Operations
Effient Election Directors
Eli Lilly Employee Litigation
Employees Entry Material Definitive Agreement
Environmental Matters Erbitux
Executive Officers Executive Overview
Exenatide Exhibits
Financial Condition Financial Expectations 2007
Financial Expectations 2008 Financial Expectations 2009
Financial Expectations 2010 Financial Information Relating Business Segments Classes Products
Financial Information Relating Foreign Domestic Operations Financial Instruments Investments
Financial Results Financial Statement Schedules
Financial Statements Form 10-k
Government Investigations Government Investigations Related Litigation
Gross Margin Costs Expenses Http Investorlillycom Seccfm
Icos Corporation Icos Corporation Acquisition
Impairment Long-lived Assets Implementation New Financial Accounting Pronouncements
Income Taxes Index Exhibits
Intellectual Property Portfolio Internal Control Over Financial Reporting
Late-stage Pipeline Developments Business Development Activity Legal Governmental Matters
Legal Proceedings Described Managements Discussion Analysis Legal Regulatory Matters
Legal Regulatory Other Matters Managements Report Financial Statements Eli Lilly Subsidiaries
Managements Report Financial Statements-eli Lilly Subsidiaries Managements Report Internal Control Over Financial Reporting Eli
Managements Report Internal Control Over Financial Reporting-eli Lilly Managements Reports
Marketing Material Impairments
Merck Kgaa Necitumumab
Notes Consolidated Financial Statements Other
Other Acquisitions Other Assets Liabilities
Other Comprehensive Income Loss Other Events
Other Marketing Practices Investigations Other Matters
Other Patent Litigation Other Product Liability Litigation
Overview Part
Patent Challenges Patent Challenges Hatch-waxman Act
Patent Licenses Patent Litigation
Pension Retiree Medical Plan Assumptions Performance Award Program
Performance Graph Pharmaceutical Marketing Collaborations
Pharmaceuticals 8722 Outside United States Pharmaceuticals 8722 United States
Pharmaceuticals Outside United States Pharmaceuticals United States
Pharmaceuticals-outside United States Pharmaceuticals-united States
Pipeline Posilac
Potential Payments Termination Change Control Prasugrel
President Chief Executive Officer Private Securities Litigation Reform Act 1995 Caution Concerning
Pro Forma Financial Information Product Acquisitions
Product Liability Insurance Product Liability Other Special Charges
Product Liability Related Litigation Product Litigation Liabilities Other Contingencies
Products Proposal Ratify Appointment Principal Independent Auditors
Quality Assurance Quintiles
Raw Materials Product Supply Regulation Disclosure
Regulation Operations Regulations Affecting Pharmaceutical Pricing Reimbursement
Related Person Transactions Report Independent Registered Public Accounting Firm
Research Development Revenue Recognition Sales Rebate Discount Accruals
Revenue Recognition Sales Return Rebate Discount Accruals Sales
Securities Authorized Issuance Equity Compensation Plans Securities Registered Pursuant Act
Security Ownership Certain Beneficial Owners Management Sgx Pharmaceuticals Inc
Shareholder Derivative Litigation Shareholder Litigation
Shareholder Proposal Regarding Amending Bylaws Shareholder Proposal Regarding Care Animals
Shareholder Proposal Regarding International Outsourcing Animal Research Shareholder Value Award Program
Signatures Stock Option Program
Stock-based Compensation Top Form
Tpg-axon Capital Zyprexa Litigation
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki